Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 17.44
AEGR's Cash to Debt is ranked higher than
77% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. AEGR: 17.44 )
AEGR' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 17.44

Equity to Asset 0.79
AEGR's Equity to Asset is ranked higher than
84% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. AEGR: 0.79 )
AEGR' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.87
Current: 0.79

0.79
0.87
F-Score: 5
Z-Score: 13.74
M-Score: 48.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -128.43
AEGR's Operating margin (%) is ranked lower than
53% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. AEGR: -128.43 )
AEGR' s 10-Year Operating margin (%) Range
Min: -128.43   Max: -128.43
Current: -128.43

Net-margin (%) -130.51
AEGR's Net-margin (%) is ranked lower than
53% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. AEGR: -130.51 )
AEGR' s 10-Year Net-margin (%) Range
Min: -130.51   Max: -130.51
Current: -130.51

ROE (%) -56.05
AEGR's ROE (%) is ranked lower than
53% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AEGR: -56.05 )
AEGR' s 10-Year ROE (%) Range
Min: -103.09   Max: -34.7
Current: -56.05

-103.09
-34.7
ROA (%) -44.51
AEGR's ROA (%) is ranked lower than
53% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. AEGR: -44.51 )
AEGR' s 10-Year ROA (%) Range
Min: -460.23   Max: -6.36
Current: -44.51

-460.23
-6.36
ROC (Joel Greenblatt) (%) -3769.47
AEGR's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. AEGR: -3769.47 )
AEGR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -84687.5   Max: -3769.47
Current: -3769.47

-84687.5
-3769.47
EBITDA Growth (%) 20.30
AEGR's EBITDA Growth (%) is ranked higher than
83% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. AEGR: 20.30 )
AEGR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 20.3
Current: 20.3

0
20.3
EPS Growth (%) 1.70
AEGR's EPS Growth (%) is ranked higher than
70% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. AEGR: 1.70 )
AEGR' s 10-Year EPS Growth (%) Range
Min: 0   Max: 1.7
Current: 1.7

0
1.7
» AEGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

AEGR Guru Trades in Q2 2013

Andreas Halvorsen 35,994 sh (New)
Steven Cohen 30,700 sh (New)
RS Investment Management 260,726 sh (-16.23%)
» More
Q3 2013

AEGR Guru Trades in Q3 2013

Jim Simons 52,800 sh (New)
Andreas Halvorsen 744,788 sh (+1969.2%)
RS Investment Management 396,386 sh (+52.03%)
Steven Cohen Sold Out
» More
Q4 2013

AEGR Guru Trades in Q4 2013

RS Investment Management 534,248 sh (+34.78%)
Andreas Halvorsen 881,333 sh (+18.33%)
Jim Simons Sold Out
» More
Q1 2014

AEGR Guru Trades in Q1 2014

Michael Price 200,000 sh (New)
RS Investment Management Sold Out
Andreas Halvorsen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2014-03-31 New Buy1.1%$43.65 - $73.75 $ 27.41-54%200000
George Soros 2012-06-30 Sold Out 0.01%$11.76 - $16.96 $ 27.4196%0
George Soros 2011-06-30 New Buy0.01%$15.29 - $21.85 $ 27.4156%37500
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Aegerion Pharmaceuticals Inc

Three CEOs Reporting Large Insider Buys
Over the past week we’ve seen several large insider buys as well as several coming from the companies’ CEOs. It is interesting to note when a CEO, or even a CFO, buys because these insiders supposedly have the most intimate knowledge of their company's workings.

Read more...

Ratios

vs
industry
vs
history
P/B 7.41
AEGR's P/B is ranked higher than
54% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. AEGR: 7.41 )
AEGR' s 10-Year P/B Range
Min: 7.12   Max: 24.56
Current: 7.41

7.12
24.56
P/S 10.75
AEGR's P/S is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. AEGR: 10.75 )
AEGR' s 10-Year P/S Range
Min: 10.56   Max: 1820.75
Current: 10.75

10.56
1820.75
EV-to-EBIT -11.54
AEGR's EV-to-EBIT is ranked lower than
57% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. AEGR: -11.54 )
AEGR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -11.54

Current Ratio 5.39
AEGR's Current Ratio is ranked higher than
88% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. AEGR: 5.39 )
AEGR' s 10-Year Current Ratio Range
Min: 0.03   Max: 17.43
Current: 5.39

0.03
17.43
Quick Ratio 5.23
AEGR's Quick Ratio is ranked higher than
89% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. AEGR: 5.23 )
AEGR' s 10-Year Quick Ratio Range
Min: 0.03   Max: 17.43
Current: 5.23

0.03
17.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.10
AEGR's Price/Net Cash is ranked higher than
93% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AEGR: 9.10 )
AEGR' s 10-Year Price/Net Cash Range
Min: 4.01   Max: 23.89
Current: 9.1

4.01
23.89
Price/Net Current Asset Value 8.25
AEGR's Price/Net Current Asset Value is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AEGR: 8.25 )
AEGR' s 10-Year Price/Net Current Asset Value Range
Min: 4.01   Max: 22.99
Current: 8.25

4.01
22.99
Price/Tangible Book 7.41
AEGR's Price/Tangible Book is ranked higher than
61% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. AEGR: 7.41 )
AEGR' s 10-Year Price/Tangible Book Range
Min: 3.9   Max: 21.65
Current: 7.41

3.9
21.65
Price/Median PS Value 0.12
AEGR's Price/Median PS Value is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. AEGR: 0.12 )
AEGR' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 11.21
Current: 0.12

0.2
11.21

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:KYE.Germany
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company. It develops into commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases.
» More Articles for AEGR

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
Weekly CFO Buys Highlight: RXN, XBKS, STAG, AEGR, PZG Apr 02 2012 

More From Our Partners
Stocks Hitting 52-Week Lows Jul 18 2014 - BENZINGA

More From Other Websites
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Jul 14 2014
A year of winners (and losers) post-'Alpha' Jul 11 2014
5-Star Biotech Stock Watch: Aegerion Pharmaceuticals Jul 09 2014
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Jul 09 2014
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Jul 09 2014
Basket Of Biotech Bargains To Buy And Hold Jun 30 2014
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 26 2014
Pittsburgh Law Office of Alfred G. Yates Jr., P.C. Files Class Action Lawsuit On Behalf of... Jun 16 2014
Aegerion Stock May See a Resurgence After Hitting Bottom From Ongoing Controveries Jun 09 2014
Aegerion grants stock options under inducement program Jun 06 2014
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Jun 06 2014
Weakness Seen in Aegerion Pharmaceuticals (AEGR) Estimates: Should You Stay Away? May 29 2014
Aegerion Pharmaceuticals Announces Presentation at the Jefferies 2014 Global Healthcare Conference May 28 2014
Aegerion initiated with a Sell at Goldman May 27 2014
Aegerion And The Orphan Drug Paradox May 23 2014
Nasdaq stocks posting largest percentage decreases May 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide